JP
Joseph C Papa (President and CEO) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Emergent BioSolutions Inc. (EBS). Across 1 priced purchase filing, the average 21-session return was +12.7% from execution and +11.4% from disclosure (delay-adjusted; derived). The largest single filing was $350K of EBS (60,000 sh × $5.83, as filed), executed May 13 2025. Data as of Nov 7 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+12.7%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+11.4%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$350K
shares × price, as filed
Last traded
May 13 2025
Filed May 15 2025
Median ADV $8.3M across their filed names
Open performance→Volume by month
Buys $350K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 24 months
Most traded names
EBS
Emergent BioSolutions Inc.
EBS · 1 buy · 0 sells
1 filing
Recent filings
EBSPURCHASE
Emergent BioSolutions Inc.
View filing →
$350K60,000 sh × $5.83
Exec May 13 2025
Filed May 15 2025 · 5:30 PM ET